Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolus, Inc.EOLS · Entity 5341 | See Remarks | May 17, 2022 | May 19, 2022 |
| HARROW, INC.HROW · Entity 4740 | Director | June 18, 2026 | June 22, 2026 |
| Revance Therapeutics, Inc.RVNC · Entity 83521 | CFO & CBO | May 22, 2018 | May 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolus, Inc.
Report date May 17, 2022 · Filed May 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 141,571 |
Ending reported balance
After 2022-05-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-17 · Sale · Disposed 16,189 · Balance 193,586 F1: The shares were sold in multiple trades at prices ranging from $13.90 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2022-05-18 · Sale · Disposed 52,015 · Balance 141,571 F2: The shares were sold in multiple trades at prices ranging from $12.15 to $13.515. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold in multiple trades at prices ranging from $13.90 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The shares were sold in multiple trades at prices ranging from $12.15 to $13.515. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
HARROW, INC.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,248 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 5,248 · Balance 5,248 F1: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered.
F2: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service.
Revance Therapeutics, Inc.
Report date May 22, 2018 · Filed May 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,497 |
Reported balance
After 2018-05-22 transaction · row 1
1 source rowRow 1 · 2018-05-22 · Sale · Disposed 2,874 · Balance 65,497 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. F2: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.50. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail.
F2: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.50. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DYNAVAX TECHNOLOGIES CORP
Report date February 10, 2026 · Filed February 10, 2026
Section 16 reporting ended · disclosed 2026-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock - Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 1
1 source rowRow 1 · 2026-02-10 · Disposition to issuer · Disposed 10,075 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.94 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-10 · Disposition to issuer · Disposed 42,750 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.18 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-10 · Disposition to issuer · Disposed 7,125 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").
F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price.
F4: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.
Harpoon Therapeutics, Inc.
Report date March 11, 2024 · Filed March 11, 2024
Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 1
1 source rowRow 1 · 2024-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.20 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-11 · Disposition to issuer · Disposed 2,033 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-11 · Disposition to issuer · Disposed 2,300 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock").
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the
F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 23:51 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 5,248 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-029658 · ownership.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,248 Underlying: Common Stock · 5,248 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2 · derivative.exercise_date: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| May 18, 2026 Filed May 19, 2026 11:00 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock | 1,000 | $31.00 | $31,000.00 |
DisclosureSEC source: 0001493152-26-024341 · ownership.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,125 | Not disclosed Strike: $10.18 | Not disclosed |
DisclosureSEC source: 0001225755-26-000002 · form4-02102026_040205.xml · derivative · entry 3 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,125 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,750 | Not disclosed Strike: $12.94 | Not disclosed |
DisclosureSEC source: 0001225755-26-000002 · form4-02102026_040205.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,750 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerCommon Stock - Restricted Stock Units | 10,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225755-26-000002 · form4-02102026_040205.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:53 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 7,339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-016324 · ownership.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,339 Underlying: Common Stock · 7,339 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2 · derivative.exercise_date: Award of Restricted Stock Units vests in full on the one-year anniversary following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests in full on the one-year anniversary following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 17:55 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Option (Right to Buy) · Derivative | 7,125 | $0.00 Strike: $10.18 | $0.00 |
DisclosureSEC source: 0001029142-25-000106 · wk-form4_1749851737.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,125 Underlying: Commont Stock · 7,125 shares Expires 2032-06-10 F2 · derivative.exercise_date: This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 17:55 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantCommon Stock | 1,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001029142-25-000106 · wk-form4_1749851737.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,075 F1 · security: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 18:29 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Option (Right to Buy) · Derivative | 42,750 | $0.00 Strike: $12.94 | $0.00 |
DisclosureSEC source: 0001029142-25-000013 · wk-form4_1738798193.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,750 Underlying: Common Stock · 42,750 shares Expires 2032-02-02 F2 · derivative.exercise_date: This option grant vests over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each vesting date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 18:29 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantRestricted Stock Unit · Derivative | 8,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000013 · wk-form4_1738798193.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,636 Underlying: Common Stock · 8,636 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:00 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 8,347 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-024192 · ownership.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,347 Underlying: Common Stock · 8,347 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2 · derivative.exercise_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 21:26 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 2,300 | Not disclosed Strike: $6.66 | Not disclosed |
DisclosureSEC source: 0000950170-24-029447 · ownership.xml · derivative · entry 3 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · price: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · derivative.exercise_date: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · derivative.expiration_date: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 21:26 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 2,033 | Not disclosed Strike: $16.20 | Not disclosed |
DisclosureSEC source: 0000950170-24-029447 · ownership.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,033 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · price: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · derivative.exercise_date: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6 · derivative.expiration_date: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 21:26 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Disposition to issuerCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-029447 · ownership.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2 · shares: Includes 5,000 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). F3 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). F1 · acquired: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:10 UTC | HARROW, INC. HROW · Entity 4740 | GrantRSU · Derivative | 3,119 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004312 · ownership.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,119 Underlying: Common Stock · 3,119 shares Expires not disclosed F1 · security: The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered. F2 · derivative.exercise_date: Award of Restricted Stock Units vests in full on June 21, 2024. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. F2 · derivative.expiration_date: Award of Restricted Stock Units vests in full on June 21, 2024. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service. Read SEC document |
| November 27, 2023 Filed Nov 28, 2023 21:29 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056799 · doc4.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock issuable upon the settlement of restricted stock units ("RSUs"). 25% of the RSUs will vest on each May 27th and November 27th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:40 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001209191-23-039424 · doc4.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on June 21, 2024, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:23 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (right to buy) · Derivative | 20,335 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-22-050515 · doc4.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,335 Underlying: Common Stock · 20,335 shares Expires 2032-09-14 F1 · derivative.exercise_date: The stock option vests in three equal annual installments measured from the date of grant, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 18, 2022 Filed May 19, 2022 00:21 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 52,015 | $12.42 | $646,026.30 |
DisclosureSEC source: 0001570562-22-000107 · wf-form4_165291965473241.xml · nonDerivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,571 F2 · price: The shares were sold in multiple trades at prices ranging from $12.15 to $13.515. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 17, 2022 Filed May 19, 2022 00:21 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 16,189 | $13.92 | $225,354.12 |
DisclosureSEC source: 0001570562-22-000107 · wf-form4_165291965473241.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,586 F1 · price: The shares were sold in multiple trades at prices ranging from $13.90 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:23 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 10,192 | $9.73 | $99,121.28 |
DisclosureSEC source: 0001570562-22-000083 · wf-form4_164695816288187.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,775 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $9.50 to $9.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:03 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 77,640 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-22-000054 · wf-form4_164324897583655.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,640 Underlying: Common Stock · 77,640 shares Expires 2032-01-25 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:03 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 53,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000054 · wf-form4_164324897583655.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,967 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 23:05 UTC Amendment | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 14,293 | $11.18 | $159,774.30 |
DisclosureSEC source: 0001570562-21-000158 · wf-form4a_162880951243721.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,396 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.3055. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 22:45 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 14,293 | $11.18 | $159,774.30 |
DisclosureSEC source: 0001570562-21-000156 · wf-form4_162880831776164.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,982 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. F2 · price: The shares were sold in multiple trades at prices ranging from $11.1762 to $11.3055. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 27, 2021 Filed Feb 2, 2021 00:29 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000019 · wf-form4_161222577187164.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,689 F1 · price: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 27, 2021, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 01:51 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 2,699 | $7.46 | $20,134.54 |
DisclosureSEC source: 0001570562-21-000012 · wf-form4_161171225932694.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,689 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the first quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units. Read SEC document |
| May 13, 2020 Filed May 15, 2020 23:59 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-20-000093 · wf-form4_158958716608299.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,388 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% of the award on July 1, 2021, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 23, 2020 Filed Jan 25, 2020 02:14 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001570562-20-000048 · wf-form4_157991846794918.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-01-23 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 23, 2020 Filed Jan 25, 2020 02:14 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-20-000048 · wf-form4_157991846794918.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,388 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| May 31, 2019 Filed May 31, 2019 23:51 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 2,612 | $13.53 | $35,352.11 |
DisclosureSEC source: 0001570562-19-000092 · wf-form4_155934669118868.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,388 F1 · shares: Represents shares sold solely for the purpose of covering tax withholding obligations in connection with the vesting and settlement of certain restricted stock units held by the reporting person previously described in a Form 4 filed on May 31, 2018. F2 · price: The shares were sold in multiple trades at prices ranging from $13.5213 to $13.5355. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2019 Filed Jan 26, 2019 01:21 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001570562-19-000024 · wf-form4_154846567750670.xml · derivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| May 29, 2018 Filed May 31, 2018 20:15 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $22.44 | $0.00 |
DisclosureSEC source: 0001570562-18-000044 · wf-form4_152779767553759.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-05-29 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 29, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| May 29, 2018 Filed May 31, 2018 20:15 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-18-000044 · wf-form4_152779767553759.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 29, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| May 22, 2018 Filed May 24, 2018 19:24 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 2,874 | $30.25 | $86,924.42 |
DisclosureSEC source: 0001479290-18-000083 · wf-form4_152720418514363.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,497 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. F2 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.50. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 21:12 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 3,431 | $30.85 | $105,838.80 |
DisclosureSEC source: 0001479290-18-000058 · wf-form4_152185393085906.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,371 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. F2 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.6501 to $31.125. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 15, 2018 Filed Mar 15, 2018 20:54 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 1,152 | $31.65 | $36,460.80 |
DisclosureSEC source: 0001479290-18-000048 · wf-form4_152116163980599.xml · nonDerivative · entry 3 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,802 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2016 Restricted Stock Award ("RSA") for 10,000 shares. The RSA vests in three (3) equal annual installments from March 15, 2016, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:54 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionStock Option (Right to buy) · Derivative | 25,867 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001479290-18-000048 · wf-form4_152116163980599.xml · derivative · entry 4 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,867 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Option became fully vested as of March 18, 2017. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:54 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 25,867 | $34.50 | $892,411.50 |
DisclosureSEC source: 0001479290-18-000048 · wf-form4_152116163980599.xml · nonDerivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 20:54 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock | 25,867 | $8.70 | $225,042.90 |
DisclosureSEC source: 0001479290-18-000048 · wf-form4_152116163980599.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2018 Filed Mar 9, 2018 20:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001479290-18-000041 · wf-form4_152064567008550.xml · derivative · entry 6 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,867 Underlying: Common Stock · 10,000 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Option became fully vested as of March 18, 2017. Read SEC document |
| March 09, 2018 Filed Mar 9, 2018 20:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 10,000 | $32.50 | $325,000.00 |
DisclosureSEC source: 0001479290-18-000041 · wf-form4_152064567008550.xml · nonDerivative · entry 4 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. Read SEC document |
| March 09, 2018 Filed Mar 9, 2018 20:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock | 10,000 | $8.70 | $87,000.00 |
DisclosureSEC source: 0001479290-18-000041 · wf-form4_152064567008550.xml · nonDerivative · entry 3 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 20:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001479290-18-000041 · wf-form4_152064567008550.xml · derivative · entry 5 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,867 Underlying: Common Stock · 10,000 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Option became fully vested as of March 18, 2017. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 20:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 10,000 | $31.50 | $315,000.00 |
DisclosureSEC source: 0001479290-18-000041 · wf-form4_152064567008550.xml · nonDerivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail. F2 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.20 to $31.85. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 20:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Exercise / conversionCommon Stock | 10,000 | $8.70 | $87,000.00 |
DisclosureSEC source: 0001479290-18-000041 · wf-form4_152064567008550.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 19:45 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 1,136 | $31.75 | $36,068.00 |
DisclosureSEC source: 0001479290-18-000029 · wf-form4_151882832124548.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,954 F1 · shares: Represents the number of shares withheld by and surrendered to the issuer on February 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award ("RSA") for 10,000 shares. The RSA vests in three (3) equal annual installments from February 15, 2017, subject to Mrs. Silvernail's Continuous Service (as defined in the 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 21:16 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $29.15 | $0.00 |
DisclosureSEC source: 0001479290-18-000021 · wf-form4_151822897304817.xml · derivative · entry 2 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2028-02-07 F2 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 8, 2018, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 21:16 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-18-000021 · wf-form4_151822897304817.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,090 F1 · shares: The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments beginning from March 15, 2018, subject to Mrs. Silvernail's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. Read SEC document |
| January 28, 2018 Filed Jan 30, 2018 21:06 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 990 | $33.50 | $33,165.00 |
DisclosureSEC source: 0001479290-18-000013 · wf-form4_151736438903990.xml · nonDerivative · entry 1 SILVERNAIL LAUREN P · CIK 0001225755 · CFO, CBO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,965 F1 · shares: Represents the number of shares withheld by and surrendered to the issuer on January 28, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2015 Restricted Stock Award ("RSA") for 7,290 shares. The RSA vests in three (3) equal annual installments from January 28, 2015, subject to Mrs. Silvernail's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan) on each vesting date. F2 · price: The fair market value was determined on January 26, 2018 per the Company Policy, as this was the last trading day before the vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.